|
|
|||||||||
(Pediatrics in Review. 2007;28:439-453.)
© 2007 American Academy of Pediatrics



Associate Professor of Surgery; Senior Associate, Department of Cardiac Surgery, Harvard Medical School, Children's Hospital Boston, Boston, Mass
Professor and Director, Pediatric Nephrology, University of Illinois at Chicago Medical Center, Chicago, Ill
Associate Professor, Transplantation and Molecular Genetics, University of Illinois at Chicago Medical Center, Chicago, Ill
| The first 300 words of the full text of this article appear below. |
| Learning Objectives |
|---|
| Introduction |
|---|
Regardless of transplant type, common themes emerge. Children differ from adults in their immune responses, in the way they metabolize many drugs, and in their susceptibility to many of the adverse effects of transplantation and immunosuppression. Drug regimens based on induction immunotherapy with interleukin-2 receptor antagonists or anti-lymphocyte antibody coupled with tacrolimus-based long-term immunosuppression have increased in prevalence. Long-term exposure to immunosuppressive medications, however, has led to increased drug-related morbidities. Hyperlipidemia, hypertension, cardiovascular disease, malignancy, and diabetes mellitus have emerged as significant concerns. Nonadherence to immunosuppressive regimens, particularly among adolescents, contributes to increased graft failure.
Despite these obstacles, posttransplant pediatric patient and graft survival have been improving steadily. Nationwide data indicate that patient and graft survival rates are equivalent to or better than adult survival rates. Successful delivery of care for the long-term well-being of these patients demands communication between the patient and a complex of many physicians, from the earliest encounters with general pediatricians to more specialized care with
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | CME | ARCHIVE | SEARCH | TABLE OF CONTENTS |